Company news

Alkermes plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alkermes to Report First Quarter Financial Results on April 27, 2022

April 19, 2022

Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica

April 18, 2022

Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

April 6, 2022

Alkermes to Participate in the Stifel 2022 CNS Days

March 21, 2022

Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer

February 28, 2022

Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium

February 16, 2022

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022

February 15, 2022

Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness

February 7, 2022

Alkermes to Report Fourth Quarter and Year-End 2021 Financial Results on Feb. 16, 2022

February 1, 2022

Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

January 17, 2022

Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference

November 23, 2021

Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

November 18, 2021

Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders

November 10, 2021

Alkermes to Take Part in the Stifel Virtual Healthcare Conference

November 8, 2021

Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica

November 7, 2021

Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

November 2, 2021

Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences

October 28, 2021

Alkermes plc Reports Third Quarter 2021 Financial Results

October 26, 2021

Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

October 25, 2021

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

October 24, 2021

Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021

October 19, 2021

Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder

October 17, 2021

Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference

September 21, 2021

Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress

September 12, 2021

Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program

September 8, 2021

Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference

September 1, 2021

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

August 1, 2021

Alkermes plc Reports Second Quarter 2021 Financial Results

July 27, 2021

Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program

July 22, 2021

Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021

July 20, 2021

Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence

July 12, 2021

Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign

June 23, 2021

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

June 3, 2021

Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference

June 2, 2021

Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder

May 31, 2021

Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 27, 2021

Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors

May 19, 2021

Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

May 12, 2021

Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference

May 4, 2021

Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month

May 2, 2021

Alkermes Announces Agreement with Sarissa Capital

April 29, 2021

Alkermes plc Reports First Quarter 2021 Financial Results

April 27, 2021

Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

April 27, 2021

Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence

April 26, 2021

Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma

April 26, 2021

Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results

April 20, 2021

Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society

April 19, 2021

Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer

April 6, 2021

Alkermes to Take Part in Stifel's 3rd Annual CNS Day

March 24, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 73 decks. Every deck is listed under its year.